A Multicenter, Phase II Clinical Study of AK104 (Anti-PD-1/CTLA-4 Bispecific Antibody) Alone or in Combination With Chemotherapy in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 80
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is a two-arm, open, multicenter clinical study to evaluate the efficacy and safety of AK104 alone or in combination with cisplatin and paclitaxel in the treatment of advanced esophageal squamous carcinoma without systemic therapy.
详细描述
During the treatment, eligible patients in cohort A with PD-L1 CPS ≥5 will receive AK104 10 mg/kg, intravenously, every 3 weeks (maximum 24 months of dosing); in cohort B, regardless of PD-L1 expression, eligible patients will receive AK104 10 mg/kg, intravenously, every 3 weeks (maximum 24 months of dosing), in combination with cisplatin (75 mg/m2) and paclitaxel (175 mg/m2), Q3W (up to 6 cycles, the specific cycles will be determined by the investigator). Thereafter, AK104 maintenance therapy will be continued until disease progression, intolerable toxicity, withdrawal of informed consent, death, or end of the study, whichever occurred first (maximum duration of treatment with AK104 should be less than 12 months). When patients with initially unresectable disease transformed into resectable, an operation can be considered and the original regimen may be used after surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 to 75 years old, men or women are not limited
- •Histologically or cytologically confirmed as esophageal squamous cell carcinoma (including the gastroesophageal junction), (adenosquamous carcinoma with a predominantly squamous component is allowed)
- •Unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
- •Patients who have never received systemic antitumor therapy
- •ECOG score 0-1
- •Patients who have measurable lesions that meet RECIST 1.1 criteria
- •Patients who are expected to survive more than 3 months
- •Women of childbearing age must have a negative pregnancy test (serum or urine) and voluntarily use an appropriate method of contraception
- •Patients who are voluntarily enrolled in the study and sign an informed consent form (ICF)
- •Patients who are well adherent and able to follow up the study protocol
- •Patients with normal function organs, no serious abnormalities of blood, heart, lung, liver, kidney function, and immunodeficiency diseases.
- •Patients with normal coagulation function, no active bleeding, and thrombotic disease
- •cohort A: AK104 monotherapy cohort enrolling patients with esophageal cancer tumor tissue PD-L1 CPS ≥ 5 (uniformly using Dako 22C3 antibody)
排除标准
- •Locally advanced esophageal cancer that can be radically resectable or potentially cured by radiotherapy
- •Other malignancies diagnosed within 5 years prior to the first administration of the study drug, except effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or effectively resected in situ cervical and/or breast cancer
- •Symptomatic central nervous system metastases (brain metastases confirmed stable by imaging for more than 3 months can be enrolled)
- •A serious infection (CTCAE > grade 2) such as severe pneumonia requiring hospitalization, bacteremia, or infectious comorbidities that occurred within 4 weeks prior to the first administration of the study drug; baseline chest imaging suggestive of active pulmonary inflammation with clinically relevant signs or symptoms; signs and symptoms of infection within 2 weeks prior to the first administration of study drug, or requiring oral, or intravenous antibiotic therapy. Excluding prophylactic use of antibiotics
- •Patients with previous and current interstitial pneumonia, pneumoconiosis, drug-related pneumonia, or severely impaired lung function that may interfere with the detection and management of suspected drug-related pulmonary toxicity; patients with radiation pneumonia within 6 months
- •Patients with active tuberculosis infection detected by history or CT examination, patients with a history of active tuberculosis infection within 1 year prior to enrollment, or patients with a history of active tuberculosis infection more than 1 year ago but without formal treatment
- •Patients previously treated with immune checkpoint inhibitors
- •Patients who have a congenital or acquired immune deficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU/ml), hepatitis C (positive for hepatitis C antibodies and HCV-RNA above the lower limit of detection of the assay) or combined hepatitis B and hepatitis C co-infection
- •Patients who have a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
- •The presence of thrombosis-type diseases or using anticoagulant drugs
- •Patients with any serious or uncontrolled systemic disease that, in the opinion of the investigator, may increase the risk associated with participation
研究组 & 干预措施
Cohort A
AK104 alone
干预措施: AK104 (Drug)
Cohort B
AK104 in combination with chemotherapy
干预措施: AK104 (Drug)
Cohort B
AK104 in combination with chemotherapy
干预措施: Cisplatin (Drug)
Cohort B
AK104 in combination with chemotherapy
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: Up to approximately 2 years
ORR is proportion of subjects with complete response(CR) or partial response(PR), based on Response Evaluation Criteria in Solid Tumors(RECIST) v1.1.
次要结局
- Progression-free survival (PFS)(Up to approximately 2 years)
- Incidence and severity of adverse events(AEs)(Up to approximately 2 years)
- Disease control rate (DCR)(Up to approximately 2 years)
- Duration of response (DoR)(Up to approximately 2 years)
- Overall survival (OS)(Up to approximately 2 years)
研究者
Jing Huang
Principal Investigator
Chinese Academy of Medical Sciences